Frontlight ResearchEarly access
IgA nephropathy trials in Taiwan
10 of 10 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleStudy to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
- Where
- Taipei, Taoyuan
- Age
- 2 years to 18 years
- People
- 28 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07498335 - Phase 3Taking peopleA Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
- Where
- Kaohsiung City, New Taipei City, Taichung, Zhongzheng
- Age
- 18 years and over
- People
- 347 worldwide
- Run by
- Takeda
See details and how to joinNCT06963827 · EU 2025-520825-19-00 - Phase 2Taking peopleA Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Where
- Kaohsiung City, New Taipei City, Taichung, Taipei, Taipei City, Taiyuan
- Age
- 18 years to 60 years
- People
- 30 worldwide
- Run by
- Jade Biosciences, Inc.
See details and how to joinNCT07541287 - Phase 2Taking peopleA Study to Assess the Effects of Zigakibart on IgA Nephropathy.
- Where
- Kaohsiung City, Taipei
- Age
- 18 years and over
- People
- 32 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07146906 · EU 2024-519699-24-00 - Phase 2Taking peoplePhase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
- Where
- Kaohsiung City, New Taipei City
- Age
- 18 years and over
- People
- 45 worldwide
- Run by
- ADARx Pharmaceuticals, Inc.
See details and how to joinNCT06989359 - Phase 3Taking peopleA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
- Where
- Dawan, Kaohsiung City, New Taipei City, Taichung, Taipei, Taoyuan
- Age
- 18 years and over
- People
- 454 worldwide
- Run by
- Biogen
See details and how to joinNCT06935357 · EU 2024-519345-30-00 - Phase 3Active, not recruitingA Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- Where
- Kaohsiung City, New Taipei City, Taichung, Taipei, Taoyuan
- Age
- 18 years to 100 years
- People
- 540 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04557462 · EU 2023-508690-92-00 - Phase 3Taking peopleOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Where
- Taipei
- Age
- 18 years to 100 years
- People
- 220 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06858319 - Phase 3Taking peopleStudy of Ravulizumab in Pediatric Participants With Primary IgAN
- Where
- Taipei, Taoyuan
- Age
- 2 years to 18 years
- People
- 36 worldwide
- Run by
- Alexion Pharmaceuticals, Inc.
See details and how to joinNCT07024563 · EU 2024-520167-13-00 - Phase 2/3Enrolling by invitationTrial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
- Where
- Kaohsiung City, Keelung, New Taipei City, Taipei
- Age
- 18 years and over
- People
- 600 worldwide
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
See details and how to joinNCT05248659